← Browse by Condition
Medical Condition

recurrent plasma cell myeloma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for recurrent plasma cell myeloma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent plasma cell myeloma Clinical Trials

How many clinical trials are currently recruiting for recurrent plasma cell myeloma?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for recurrent plasma cell myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent plasma cell myeloma?
recurrent plasma cell myeloma research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent plasma cell myeloma clinical trial?
Eligibility criteria for recurrent plasma cell myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
Mayo Clinic 1 trial

Recruiting Clinical Trials

NCT03017820 Phase 1
Recruiting
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Enrollment
99 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →

Related Conditions

b cell non hodgkin lymphoma (1) histiocytic and dendritic cell neoplasm (1) myelodysplastic syndrome (1) previously treated myelodysplastic syndrome (1) recurrent adult acute myeloid leukemia (1) recurrent anaplastic large cell lymphoma (1) recurrent angioimmunoblastic t cell lymphoma (1) recurrent mycosis fungoides (1) recurrent primary cutaneous t cell non hodgkin lymphoma (1) recurrent t cell non hodgkin lymphoma (1) refractory acute myeloid leukemia (1) refractory anaplastic large cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology